Wandel, Simon
Novartis (Switzerland)
4 papers on CoChatORCID 0000-0002-1442-597X
Most cited papers
- Verified
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology
Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management
Cited by 640
- Verified
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis
Stettler, C., Allemann, S., Wandel, S., Kastrati, A., Morice, M. C., Schomig, A., Pfisterer, M. E., Stone, G. W., Leon, M. B., Lezo, J. S. D., et al. (2008) · BMJ
Coronary Interventions and DiagnosticsAntiplatelet Therapy and Cardiovascular Diseases
Cited by 320
- Verified
Meta‐analysis of two studies in the presence of heterogeneity with applications in rare diseases
Friede, T., Röver, C., Wandel, S., & Neuenschwander, B. (2017) · Biometrical Journal
Meta-analysis and systematic reviewsStatistical Methods in Clinical Trials
Cited by 128
- Verified
Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study
Tendal, B., Higgins, J. P. T., Juni, P., Hrobjartsson, A., Trelle, S., Nuesch, E., Wandel, S., Jorgensen, A. W., Gesser, K., Ilsoe-Kristensen, S., et al. (2009) · BMJ
Meta-analysis and systematic reviewsReliability and Agreement in Measurement
Cited by 77
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free